Overview

Empagliflozin in Pulmonary Arterial Hypertension

Status:
Not yet recruiting

Trial end date:
2024-11-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to determine whether conducting a randomized placebo-controlled clinical trial is feasible, safe for the patient and whether the treatment is well tolerated in patients with idiopathic pulmonary arterial hypertension.

Phase:

Phase 2

Details

Lead Sponsor:

Amsterdam UMC, location VUmc

Treatments:

Empagliflozin